Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

TRICAV-II Pivotal: TRIcvalve biCAVal ventilový systém pro těžkou trikuspidální regurgitaci. (TRICAV-II)

12. listopadu 2026 aktualizováno: P+F Products + Features USA Inc.

Prospektivní, multicentrická, randomizovaná, klinická studie TricValve transkatétrového bikaválního ventilového systému u pacientů s těžkou trikuspidální regurgitací (TR).

Pivotal trial to evaluate the safety and effectiveness of the P&F TricValve® Transcatheter Bicaval Valve System.

Přehled studie

Detailní popis

The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the TricValve System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with severe tricuspid regurgitation and unsuitable for approved transcatheter therapies. Subjects will be followed at discharge, 1 month, 30 days, 3 months, 6 months 12 months, and annually up to 5 years.

Typ studie

Intervenční

Zápis (Odhadovaný)

780

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Alabama
      • Birmingham, Alabama, Spojené státy, 35233
        • University of Alabama
    • Arizona
      • Phoenix, Arizona, Spojené státy, 85013
        • St. Joseph's Hospital and Medical Center
    • California
      • Sacramento, California, Spojené státy, 95817
        • UC Davis Health
      • San Diego, California, Spojené státy, 92037
        • Scripps Memorial Hospital La Jolla
      • San Francisco, California, Spojené státy, 94143
        • UCSF
      • San Jose, California, Spojené státy, 94118
        • Kaiser Permanente
        • Vrchní vyšetřovatel:
          • Andrew Rassi, MD
        • Kontakt:
    • District of Columbia
      • Washington D.C., District of Columbia, Spojené státy, 20010
        • MedStar Washington Hospital Center (MWHC)
        • Kontakt:
          • Erin Collins
        • Vrchní vyšetřovatel:
          • Toby Rogers, MD
    • Florida
      • Delray Beach, Florida, Spojené státy, 33484
        • Delray Medical Center
      • Largo, Florida, Spojené státy, 33770
      • Tampa, Florida, Spojené státy, 33606
        • Tampa General Hospital
    • Illinois
      • Glenview, Illinois, Spojené státy, 60026
        • Endeavor Health
    • Indiana
      • Indianapolis, Indiana, Spojené státy, 46260
        • Ascension Medical Group St. Vincent The Heart Center of Indiana
    • Kansas
      • Kansas City, Kansas, Spojené státy, 66103
        • University of Kansas Medical Center
    • Louisiana
      • Houma, Louisiana, Spojené státy, 70360
        • Cardiovascular Institute of the South
        • Vrchní vyšetřovatel:
          • Peter Fail, MD
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Spojené státy, 02114
        • Massachusetts General Hospital
      • Burlington, Massachusetts, Spojené státy, 01805
        • Lahey Hospital & Medical Center
    • Minnesota
      • Minneapolis, Minnesota, Spojené státy, 55407
        • Minneapolis Heart Institute Foundation
    • Missouri
      • Kansas City, Missouri, Spojené státy, 64111
        • Saint Luke's Mid America Heart Institute
      • St Louis, Missouri, Spojené státy, 63110
        • Washington University of St Louis
    • New Jersey
      • Hackensack, New Jersey, Spojené státy, 07601
        • Hackensack University Medical Center
    • New York
      • Manhasset, New York, Spojené státy, 11030
        • Northwell Hospital
      • The Bronx, New York, Spojené státy, 10467
        • Montefiore Medical Center
    • Ohio
      • Cleveland, Ohio, Spojené státy, 44106
        • Cleveland Clinic
        • Vrchní vyšetřovatel:
          • Rishi Puri, MD
      • Columbus, Ohio, Spojené státy, 43214
        • Riverside Methodist Hospital
    • Oregon
      • Portland, Oregon, Spojené státy, 97239
        • Oregon Health
        • Vrchní vyšetřovatel:
          • Firas Zahr, MD
        • Kontakt:
    • South Carolina
      • Charleston, South Carolina, Spojené státy, 29425
        • MUSC
    • Texas
      • Houston, Texas, Spojené státy, 77030
        • Houston Methodist
      • Houston, Texas, Spojené státy, 77030
        • University of Texas (Memorial Hermann)
      • Plano, Texas, Spojené státy, 75093
        • Baylor Scott & White Medical
    • Utah
      • Murray, Utah, Spojené státy, 84107
        • Intermountain Heart Institute - Intermountain Medical Center
        • Vrchní vyšetřovatel:
          • Brian Whisenant, MD
        • Kontakt:
    • Virginia
      • Charlottesville, Virginia, Spojené státy, 22903
        • UVA School of Medicine
      • Norfolk, Virginia, Spojené státy, 23507
        • Sentara Healthcare
      • Roanoke, Virginia, Spojené státy, 24014
        • Carilion Clinic

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 85 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Eligibility Criteria for Randomized Cohort:

Inclusion Criteria:

  1. Age between 18 years and 85 years old, at the time of signing the informed consent.
  2. Severe tricuspid regurgitation (TR) and Caval Reflux (CR), as determined by the qualifying transthoracic echocardiogram (TTE) confirmed by an echocardiography Core Lab. TVARC criteria will be used for the definition of TR severity.
  3. NYHA Class II-III-IVa (not on inotropes, IABP or LVAD) or heart failure (HF) admission in the past 6 months.
  4. Adequately treated with optimal medical therapy (OMT) for heart failure per the local Heart Team at the time of TR assessment for eligibility (TTE). OMT includes stable oral diuretic medications.
  5. High risk for open surgery and is appropriate for transcatheter tricuspid therapies according to the local heart team.
  6. Patient is unsuitable for approved transcatheter therapies and is eligible for the TricValve procedure, based on review of screening/baseline data and imaging core lab measurements by Central Screening Committee.
  7. For females of childbearing potential, negative pregnancy test.
  8. Capable and willing to provide signed informed consent

Exclusion Criteria:

CONCOMITANT PROCEDURES

  1. Patient had a recent MI, stroke, or cardiovascular accident; underwent coronary artery bypass graft surgery, had a percutaneous coronary intervention or other major cardiovascular surgery within 90 days prior to TricValve implantation.

  2. Patient requires another planned major cardiac procedure, including left-sided transcatheter intervention or surgery (e.g. severe aortic stenosis, severe mitral regurgitation), coronary artery bypass or PCI or pulmonary valve correction.

    CARDIOVASCULAR CONDITIONS

  3. LVEF ≤ 30% on echocardiography.

  4. Evidence of intracardiac, inferior vena cava (IVC), or femoral venous mass, thrombus or vegetation.

  5. Severe right ventricular dysfunction.

  6. Cardiac amyloidosis.

  7. Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or right heart catheterization.

  8. Lower extremity venous thrombosis and/or the presence of an IVC filter at the time of or 6 months prior to the TricValve procedure.

  9. Hemodynamically significant pericardial effusion.

  10. Hemodynamic instability, cardiogenic shock, inotropic support, intra-aortic balloon pump or acute heart failure within 30 days prior to the TricValve procedure.

  11. Patient with refractory heart failure requiring advanced intervention (i.e. left ventricular assist device, transplantation) (ACC/ AHA/ ESC/ EACTS Stage D heart failure).

  12. Presence of significant congenital or acquired heart disease such as RV dysplasia, arrhythmogenic RV or other conditions that could interfere with the TricValve procedure.

    ALLERGIES / INTOLERANCE

  13. Any known allergy or hypersensitivity to nitinol, bovine tissue, or contrast media that cannot be adequately treated with pre-medication.

  14. Unable to tolerate anticoagulation/antiplatelet therapy

    COMORBIDITIES

  15. Any known life-threatening condition with an estimated life span of less than 12 months.

  16. Platelet count < 75,000/mm3

  17. Child-Pugh Severity Class C (10-15 points).

  18. Severe renal insufficiency with estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2 or requiring chronic renal replacement therapy at the time of enrollment.

  19. Endocarditis or active/ongoing infection requiring antibiotics.

  20. Unable to walk at least 100 meters in a 6-minute walk test.

  21. Known bleeding or clotting disorders or patient refuses blood transfusion.

  22. Active gastrointestinal (GI) bleeding within 3 months of TricValve procedure.

  23. Prior Malignancy: this study excludes participants at material risk of near-term cancer-related morbidity/mortality that could confound 12-month outcomes. This study allows the inclusion of fully treated, remote malignancies with documented No Evidence of Disease (NED)" criteria

    a. History of any malignancy within 5 years prior to randomization or any active malignancy, except: i. Adequately treated non-melanoma skin cancer (basal or squamous cell) with no evidence of disease, or ii. Carcinoma in situ (e.g., cervical, breast DCIS) treated with curative intent and no evidence of disease.

    b. Participants with a prior malignancy diagnosed >5 years before randomization are eligible if they meet all of the "No Evidence of Disease (NED)" criteria as specified below: i. No signs/symptoms of cancer on history and physical exam per standard of care; ii. No radiologic evidence of disease on surveillance imaging if such imaging is routinely indicated for that tumor type (not protocol-mandated); iii. Tumor markers (if applicable for that cancer) not suggestive of recurrence (e.g., stable/undetectable within site's lab reference and oncologist's judgment); iv. No active anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, targeted therapy, radiotherapy) and none planned; v. Treating oncologist's attestation (or primary physician if oncology follow-up is complete) that the participant is disease-free and appropriate for participation.

    GENERAL EXCLUSIONS

  24. Use or participation in other investigational device or drug study in which the patient has not reached a primary endpoint to treat cardiovascular conditions related to the outcomes of the current study.

  25. Any other condition that would preclude the ability to meet study requirements in the opinion of the investigator.

  26. Psychiatric/behavioral issues or other medical or social conditions that preclude valid consent and follow-up

  27. Pregnant or breastfeeding subjects and those who plan pregnancy during the clinical investigation follow-up period.

Eligibility Criteria for Single Arm Cohort:

Inclusion Criteria:

  1. Age > 85 years.
  2. NYHA Class III-IV, on intravenous inotropes, IABP or LVAD.
  3. LVEF ≤ 30% on echocardiography.
  4. Severe RV dysfunction.
  5. Severe pulmonary hypertension (PH), defined as Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or mean Pulmonary Artery Pressure (mPAP >35) by right heart catheterization.
  6. Renal insufficiency: eGFR between 25 and 30 mL/min/ 1.73 m² or on chronic renal replacement therapy.
  7. Patient unable to walk a minimum distance of 100 mt during 6 minute walk test.
  8. Prior malignancy not meeting the requirements applied for the Randomized Cohort, specified in Exclusion Criterion #23.
  9. Comorbidities precluding inclusion in the Randomized Cohort (exclusion criteria #15 to #24).

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: TricValve System + Optimal medical therapy (OMT)

Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy (OMT) in patients with caval reflux and tricuspid regurgitation.

• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy

Ostatní jména:
  • Heterotopic caval valve implantation (CAVI)

Optimal medical therapy

Ostatní jména:
  • OMT
Aktivní komparátor: Optimal medical therapy (OMT) Alone

OMT alone in patients with caval reflux and tricuspid regurgitation

Optimal medical therapy

Ostatní jména:
  • OMT
Experimentální: TricValve Single Arm Registry

Single-Arm Registry for Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with OMT in patients with caval reflux and tricuspid regurgitation who are not eligible for randomization

• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy

Ostatní jména:
  • Heterotopic caval valve implantation (CAVI)

Optimal medical therapy

Ostatní jména:
  • OMT

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Randomized Cohort: Caval Reflux (CR) grade reduction
Časové okno: 6 months

Reduction in Caval Reflux (CR) assessed by the echocardiography core laboratory. The CR will be assessed using the 3-grade scale: Grade 1 (no reflux, reflux extending for less than 1 cm below the diaphragm), Grade 2 ( reflux extending for less than 3 cm), Grade 3 (reflux of 3 cm or more). Lower grades of CR are better.

6 months
Randomized Cohort: Hierarchical composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement
Časové okno: 6 months

Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm.

6 months
Randomized Cohort: Rate of Major Adverse Events (MAE)
Časové okno: 30 days

Rate of Major Adverse Events (MAE) in experimental arm (TricValve + OMT)

30 days
Randomized Cohort: Hierarchical composite endpoint: all-cause mortality, RVAD implantation or heart transplant, tricuspid valve surgery or percutaneous tricuspid intervention, heart failure hospitalizations, KCCQ improvement, NYHA functional class improv
Časové okno: 1 year

Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm.

1 year
Registry Cohort: Rate of Major Adverse Events (MAE)
Časové okno: 30 days

Rate of Major Adverse Events (MAE) in single arm registry

30 days

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Randomized Cohort: Percentage of Device- and/or Procedure-related MAEs
Časové okno: 1 year

Rate of Major Adverse Events

1 year
Randomized Cohort: All-Cause mortality and Cardiovascular Mortality
Časové okno: 6 months and 1 year

Number of deaths from any cause as well as cardiovascular events

6 months and 1 year
Randomized Cohort: Heart Failure Hospitalizations (HFH)
Časové okno: 6 months and 1 year

Number of Heart Failure Hospitalizations and worsening HF events without hospitilization

6 months and 1 year
Randomized Cohort: RVAD Implantation or Heart Transplant
Časové okno: 6 months and 1 year

Number of patients requiring RVAD Implantation or Heart Transplant

6 months and 1 year
Randomized Cohort: Atrial Fibrillation
Časové okno: 1 year

New onset of atrial fibrillation

1 year
Randomized Cohort: Quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) .
Časové okno: 6 months and 1 year

Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL)

6 months and 1 year
Randomized Cohort: Changes in symptom status New York Heart Association (NYHA class)
Časové okno: 6 months and 1 year

Reduction of at least 1 class from baseline. The NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

6 months and 1 year
Randomized Cohort: Changes in functional capacity (6-minute walk test, 6MWT).
Časové okno: 6 months and 1 year

Improvement of 6-minute walk distance of at least 30 meters from baseline.

6 months and 1 year
Registry Cohort: Heart Failure Hospitalization
Časové okno: 1 year

Comparison of the 12-month post-procedure HFH rate with the 12-month pre-procedure rate

1 year
Registry Cohort: Changes in Quality of life (by Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score).
Časové okno: 1 year

Change from baseline to 12 months. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL)

1 year
Roll-In Cohort: Percentage of Device- and/or Procedure-related MAEs
Časové okno: 1 year

Rate of Major Adverse Events

1 year
Roll-In Cohort: All-Cause mortality and Cardiovascular Mortality
Časové okno: 6 months and 1 year

Number of deaths from any cause as well as cardiovascular events

6 months and 1 year
Roll-In Cohort: Heart Failure Hospitalizations (HFH)
Časové okno: 6 months and 1 year

Number of Heart Failure Hospitalizations and worsening HF events without hospitalization

6 months and 1 year
Roll-In Cohort: RVAD Implantation or Heart Transplant
Časové okno: 6 months and 1 year

Number of patients requiring RVAD Implantation or Heart Transplant

6 months and 1 year
Roll-In Cohort: Atrial Fibrillation
Časové okno: 1 year

New onset of atrial fibrillation

1 year
Roll-In Cohort: Quality of life as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ).
Časové okno: 6 months and 1 year

Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life

6 months and 1 year
Roll-In Cohort: New York Heart Association (NYHA) functional class
Časové okno: 6 months and 1 year

Reduction of at least 1 class from baseline. NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

6 months and 1 year
Roll-In Cohort: 6-minute walk test (6MWT).
Časové okno: 6 months and 1 year

Improvement of 6-minute walk distance of at least 30 meters from baseline.

6 months and 1 year

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. listopadu 2026

Primární dokončení (Odhadovaný)

1. listopadu 2028

Dokončení studie (Odhadovaný)

1. listopadu 2032

Termíny zápisu do studia

První předloženo

7. června 2024

První předloženo, které splnilo kritéria kontroly kvality

12. června 2024

První zveřejněno (Aktuální)

14. června 2024

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

17. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

12. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • CTP-TRIC-005-II

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ano

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit